✦ LIBER ✦

Acute Myeloid Leukemia After Myelodysplastic Syndrome and Failure of Therapy With Hypomethylating Agents: An Emerging Entity With a Poor Prognosis

✍ Scribed by Jabbour, Elias; Ghanem, Hady; Huang, Xuelin; Ravandi, Farhad; Garcia-Manero, Guillermo; O'Brien, Susan; Faderl, Stephan; Pierce, Sherry; Choi, Sangbum; Verstovsek, Srdan; Brandt, Mark; Cortes, Jorge; Kantarjian, Hagop

Book ID: 121719036
Publisher: Elsevier
Year: 2014
Tongue: English
Weight: 373 KB
Volume: 14
Category: Article
ISSN: 2152-2650
DOI: 10.1016/j.clml.2013.10.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Acute Myeloid Leukemia (AML) Following M

Acute Myeloid Leukemia (AML) Following Myelodysplastic Syndrome (MDS) and Failure of Therapy with Hypomethylating Agents (HMA): An Emerging Entity With a Poor Prognosis

✍ Ghanem, Hady; Jabbour, Elias; Huang, Xuelin; Ravandi, Farhad; Garcia-Manero, Gui 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 137 KB

A randomized trial of liposomal daunorub

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

✍ Jorge Cortes; Hagop Kantarjian; Maher Albitar; Deborah Thomas; Stefan Faderl; Ch 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB

## Abstract ## BACKGROUND Because angiogenesis may play a role in the pathogenesis of acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (MDS), and thalidomide (Th) has shown significant anti‐angiogenic activity, this study was designed to investigate the potential role of Th in t